In 2014 the Straumann® Dental Implant System offers more value for dental clinicians and patients. Our product range focuses on the groundbreaking Roxolid® material, which is specifically designed for the use in dental implantology. Outstanding biological and mechanical properties allow Roxolid® Implants to offer more treatment options than conventional titanium implants.

More treatment options with smaller implants: the reduced-diameter Roxolid® Implants with the hydrophilic SLActive® surface and higher strength revolutionized the market in 2009. At the EAO 2013 Straumann launched a new range of sizes of Roxolid® SL-

Active® Implants as well as a 4 mm Roxolid® SLActive® Implant. This Roxolid® SLActive® Short Implant is designed to avoid extensive bone augmentation procedures. Now, in 2014 for the first time, Roxolid® Implants are also available with the well-established SLA® surface. Roxolid® – setting new standards, reducing invasiveness: offering all implants with the Roxolid® material helps dental professionals to reduce the invasiveness of implant treatments by using smaller, shorter implants which are stronger than conventional titanium implants. Roxolid® helps to avoid patient trauma, pain and discomfort while saving time and money.

Clinical studies and early results from clinicians after an extensive prelaunch period confirm it possesses optimal handling qualities, maintains its size when hydrated and is very tear-resistant. The optimal fit can be found without extensive trimming which limits waste and minimizes costs for both clinicians and patients. The creos xeno.protect membrane has an extended barrier function that does not compromise on the established high industry standards for biocompatibility or vascularization behavior. As it is produced without any chemical crosslinking, creos xeno.protect offers high tissue compatibility for fast and predictable healing.

1 Clinical studies, product information and first user feedback are available at creos.com/xeno-protect.

LARADO

Implant test unit allows testing during production

Implant systems are normally tested according to the DIN EN ISO 14801 Norm before they are launched. LARADO presents an especially developed dental implant testing unit—DORA 14801—which guarantees the observance and consistency for product quality before and during production and also allows for immediate design modifications. The DIN EN ISO 14801 Norm concerns itself with the testing of dental implants regarding wear and failures caused by alternating stress or loads. The DORA 14801 provides a simple and economic solution for testing with a maximum of efficiency regarding cost and time. In principle, it relates to the quality of implants which must be insured not only in the development phase, but also in later production by batch and ISO 14801-exams. Thus, a high level of security is obtained with respect to endurance, connection and structure of implants. The main factor of efficiency is obtained through one master control unit and is the basis for the connection of 1 to 8 individual test stations that provides independent, validated and documented test results. A variable sinus amplitude and dynamic-power of up to 800 N at a variable of 1–15 Hz, a low-space requirement for machine placement, the simple connection to a 110–230-volt power-outlet and the independence from compressed air or hydraulic systems are some of the advantages of the DORA 14801.

Nobel Biocare

Entering the regenerative field

Nobel Biocare launches its latest innovation, creos xeno.protect, beginning in the European markets. This new collagen membrane will be part of a larger regenerative product line under the brand name “creos”. Additional products will follow this year. “The introduction of creos xeno.protect emphasises Nobel Biocare’s long-standing commitment to improving quality of life through innovation. It is a product that harnesses the ingenuity of nature to the benefit of the patient, while at the same time making life easier for the clinician,” said Nobel Biocare CEO, Richard Laube.

Clinical studies and early results from clinicians after an extensive prelaunch period confirm it possesses optimal handling qualities, maintains its size when hydrated and is very tear-resistant. The optimal fit can be found without extensive trimming which limits waste and minimizes costs for both clinicians and patients. The creos xeno.protect membrane has an extended barrier function that does not compromise on the established high industry standards for biocompatibility or vascularization behavior. As it is produced without any chemical crosslinking, creos xeno.protect offers high tissue compatibility for fast and predictable healing.
Planmeca manufacturer news

Planmeca Less is more: Planmeca has the Ultra-Low Dose Mode

Planmeca, the Finnish dental equipment manufacturers, have developed the Ultra-Low Dose Mode.

The lowest effective radiation level to which a patient is exposed is just 14.4 µSv for a 3-D image of the entire skull. All Planmeca ProMax 3-D units enable CBCT imaging with a lower radiation dose than conventional 2-D panorama X-ray technology.

The cutting-edge Ultra-Low Dose protocol is based on Planmeca’s own intelligent 3-D algorithm, providing detailed anatomic information despite the minimal radiation level.

“We measure the radiation dosage of the ProMax units according to the effective dose measurement protocol described by Ludlow et al.” The effective dose is calculated in accordance with the revised guidelines issued by the International Commission on Radiological Protection (ICRP 103), explains Juha Koivisto, a physicist employed in Planmeca’s Research & Development department.

The Ultra-Low Dose Mode is of invaluable assistance in pre-operative planning, monitoring the treatment and locating impacted or displaced teeth. In addition to facilitating the definition of facial asymmetry and cephalometric reference points, it even supports informative sinus imaging or the measuring of the respiratory tract in diagnostics.

All Planmeca ProMax X-ray units provide a wide range of pre-programmed, easily adjustable imaging modalities for all volume sizes while effectively eliminating interference and artefacts like shadows and flickering lines from the CBCT images.


Register now for the 5th International CAMLOG Congress in Valencia

From 26 to 28 June 2014, the 5th International CAMLOG Congress will be held in Valencia under the motto “The Ever Evolving World of Implant Dentistry”. Renowned experts from Europe, Asia and America will be presenting current results from their research and clinical experience. In eight workshops, experienced specialists will convey the latest technologies and treatment methods.

Several hundred dentists and dental surgeons have already registered.

Since the first congress in 2006 and the founding of the CAMLOG Foundation, the international CAMLOG Congresses have established themselves as the most important communications and further education event in implant dentistry. Top-level speakers, practice-oriented workshops and an attractive location for the event highlight the 5th CAMLOG Congress: the international elite of dental surgeons and dental implantologists makes the spectacular Palau de les Arts in Valencia its meeting place. The established scientific committee of the CAMLOG Foundation, chaired by Prof. Mariano Sanz and Prof. Fernando Guerra, is responsible for the program.

The surgical and prosthetic concepts and treatment guidelines, which are presented in two sessions, are based on the CAMLOG Foundation Consensus, which was prepared over several meetings by experts from up to 18 countries.

Planmeca Vertriebs GmbH
Walther-Rathenau-Str. 59
33602 Bielefeld, Germany
www.planmeca.com

DENTSPLY Implants designs and produces patient-specific abutments and implant superstructures. These original CAD/CAM restorations are compatible with all major implant systems while offering perfect fit to each patient’s oral anatomy. Quality, price as well as prompt delivery save time and resources. Dr. James G. Hannooch, who was involved in the development of the ATLANTIS™ abutment concept from day one, is convinced of the systems advantages: “The patient-specific implant prostheses offer a high economic benefit whilst at the same time achieving a very high level of patient satisfaction, both reasons why today, ATLANTIS™ acts as market leader with more than one million abutments sold.”

ATLANTIS™ abutments are available for both cement-retained and single-tooth screw-retained restorations for all major implant systems. Using the patented VAD™ software (Virtual Abutment Design), the patient-specific CAD/CAM-abutment is designed based on the final tooth shape.

DENTSPLY Implants
Steinzeugstraße 50
68229 Mannheim, Germany
www.dentsplyimplants.com

DENTSPLY Implants

CAMLOG Foundation
Margarethenstrasse 38,
4053 Basel, Switzerland
www.camlogfoundation.org

Planmeca

DENTSPLY Implants